Results of dasatinib therapy in patients with early chronic-phase chronic myeloid leukemia.

ABSTRACT:

Purpose

Dasatinib is effective therapy for chronic myeloid leukemia (CML) after imatinib failure. In this study, we investigate the efficacy of dasatinib as initial therapy for patients with CML in early chronic phase.

Patients and methods

Patients with newly diagnosed CML in early chronic phase were randomly assigned to receive dasatinib 100 mg once daily or 50 mg twice daily as initial therapy.

Results

Among 50 patients observed for at least 3 months, 49 patients (98%) achieved a complete cytogenetic response (CCyR), and 41 patients (82%) achieved a major molecular response (MMR). Responses occurred rapidly, with 94% of patients achieving CCyR by 6 months. There was no difference in response rate by treatment arm. The projected event-free survival rate at 24 months

SUBMITTER: Cortes JE 

PROVIDER: S-EPMC2815702 | biostudies-literature | 2010 Jan

REPOSITORIES: biostudies-literature